Chronic Myelogenous Leukemia Research Program
Chronic Myelogenous Leukemia Research Program Cover Image

» Click on Image to View Program Booklet

Vision

To perfect the existing and develop new diagnostic and therapeutic approaches for chronic myelogenous leukemia.

Mission

To sponsor basic and clinically oriented research in the field of chronic myelogenous leukemia.

Chronic Myelogenous Leukemia Research News

Coming Soon!

more…

Chronic myelogenous leukemia (CML) is also known as chronic granulocytic leukemia or chronic myeloid leukemia. CML is an overgrowth of granulocytes, a type of white blood cell; its cause is unknown. The disease accounts for about 20 percent of adult leukemias in Western countries. This year, approximately 5,050 individuals will be diagnosed with CML, and an estimated 470 will die from the disease. In most cases, CML is characterized by a chromosomal abnormality that is known as the Philadelphia chromosome. Treatment usually consists of various chemotherapeutic agents used to disrupt the production of leukemic cells. These treatments may be followed by stem cell transplant.

ARP

Congressional Appropriations

CMLRP

Funding Summary

CMLRP

Integration Panels